Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analyst consensus: Six brokers give Acrivon a consensus rating of "Moderate Buy" (four buys, one hold, one sell) with an average 12‑month target price of about $11.67.
• Valuation and earnings: Shares recently opened at $1.64 (52‑week range $1.05–$3.56) with a market cap of $63.5M, a negative P/E, and last quarter EPS of ($0.49); analysts expect roughly ‑$2.49 EPS for the current fiscal year.
• Institutional interest and pipeline: Institutions own 71.62% of the stock with notable new or expanded stakes from UBS, Two Sigma, Invesco, Jane Street and others, while Acrivon is a clinical‑stage biotech developing stapled peptides, including a lead candidate targeting KRAS G12C.

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the six brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $11.6667.

A number of analysts have commented on ACRV shares. Wall Street Zen cut shares of Acrivon Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, March 1st. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Acrivon Therapeutics in a research report on Monday, December 29th. Jefferies Financial Group reiterated a "buy" rating on shares of Acrivon Therapeutics in a research note on Monday, March 2nd. Finally, Piper Sandler increased their price objective on shares of Acrivon Therapeutics from $6.00 to $8.00 and gave the company an "overweight" rating in a research note on Friday, January 9th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Invesco Ltd. bought a new stake in shares of Acrivon Therapeutics during the 1st quarter worth $72,000. XTX Topco Ltd purchased a new position in Acrivon Therapeutics in the 2nd quarter worth $126,000. Jane Street Group LLC purchased a new position in Acrivon Therapeutics in the 2nd quarter worth $371,000. UBS Group AG raised its position in Acrivon Therapeutics by 150,057.8% in the 3rd quarter. UBS Group AG now owns 683,218 shares of the company's stock worth $1,237,000 after purchasing an additional 682,763 shares during the period. Finally, Two Sigma Investments LP raised its position in Acrivon Therapeutics by 76.2% in the 3rd quarter. Two Sigma Investments LP now owns 319,205 shares of the company's stock worth $578,000 after purchasing an additional 138,033 shares during the period. 71.62% of the stock is owned by institutional investors.

Acrivon Therapeutics Price Performance

Shares of ACRV opened at $1.64 on Wednesday. Acrivon Therapeutics has a one year low of $1.05 and a one year high of $3.56. The company has a market cap of $63.53 million, a P/E ratio of -0.81 and a beta of 1.72. The firm has a 50 day simple moving average of $1.58 and a two-hundred day simple moving average of $1.94.

Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) last announced its quarterly earnings results on Thursday, March 19th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.49). On average, analysts expect that Acrivon Therapeutics will post -2.49 earnings per share for the current fiscal year.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics NASDAQ: ACRV is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company's lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.